218,336 Shares in Pacira BioSciences, Inc. (NASDAQ:PCRX) Bought by Empowered Funds LLC

Empowered Funds LLC purchased a new stake in Pacira BioSciences, Inc. (NASDAQ:PCRX) in the third quarter, HoldingsChannel reports. The fund purchased 218,336 shares of the company’s stock, valued at approximately $3,286,000.

Several other hedge funds and other institutional investors also recently bought and sold shares of PCRX. GAMMA Investing LLC lifted its stake in shares of Pacira BioSciences by 229.6% in the second quarter. GAMMA Investing LLC now owns 1,338 shares of the company’s stock valued at $38,000 after buying an additional 932 shares during the period. Park Place Capital Corp acquired a new stake in shares of Pacira BioSciences during the 2nd quarter worth approximately $46,000. Innealta Capital LLC bought a new stake in shares of Pacira BioSciences during the second quarter valued at approximately $50,000. nVerses Capital LLC raised its stake in shares of Pacira BioSciences by 800.0% in the second quarter. nVerses Capital LLC now owns 1,800 shares of the company’s stock valued at $51,000 after purchasing an additional 1,600 shares in the last quarter. Finally, Natixis bought a new position in Pacira BioSciences in the first quarter worth $95,000. 99.73% of the stock is currently owned by institutional investors and hedge funds.

Pacira BioSciences Stock Up 0.2 %

Shares of NASDAQ:PCRX opened at $16.64 on Tuesday. Pacira BioSciences, Inc. has a 12 month low of $11.16 and a 12 month high of $35.95. The firm has a market cap of $768.32 million, a P/E ratio of -8.20 and a beta of 0.82. The company has a quick ratio of 1.89, a current ratio of 2.25 and a debt-to-equity ratio of 0.51. The company’s 50-day moving average price is $15.81 and its two-hundred day moving average price is $20.60.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on PCRX. Truist Financial lowered shares of Pacira BioSciences from a “buy” rating to a “sell” rating and lowered their price target for the company from $30.00 to $8.00 in a report on Tuesday, August 13th. Royal Bank of Canada increased their price target on shares of Pacira BioSciences from $15.00 to $16.00 and gave the stock a “sector perform” rating in a research report on Thursday, November 7th. Needham & Company LLC reaffirmed a “buy” rating and set a $22.00 price objective on shares of Pacira BioSciences in a report on Friday, November 8th. Piper Sandler cut Pacira BioSciences from an “overweight” rating to a “neutral” rating and dropped their target price for the stock from $42.00 to $11.00 in a report on Monday, August 12th. Finally, JPMorgan Chase & Co. reaffirmed an “underweight” rating and issued a $10.00 price target (down previously from $45.00) on shares of Pacira BioSciences in a research note on Monday, August 12th. Two analysts have rated the stock with a sell rating, four have given a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $23.50.

Pacira BioSciences Company Profile

Pacira BioSciences, Inc engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves.